ACC 2019 An analysis of DECLARE-TIMI 58 showed that dapagliflozin was associated with reduced hospitalization for HF and CV death across a range of EF. Benefit seems largest in HFrEF.

ACC 2019 The new guideline promotes a healthy lifestyle throughout life, and encourages physicians to assess social determinants of health to optimally implement the recommendations.

A mendelian randomization approach to identify gut bacteria with a causal effect on metabolic traits, revealed causal links between gut-produced short-chain fatty acids and the insulin response and risk of T2DM.

A study with representative US citizens showed similar trends for most CV risk factors between men and women from 2001 to 2016, with the exception of BMI and total cholesterol, and sex differences for control of hypertension, diabetes and dyslipidemia.

The Phase III THEMIS trial demonstrated that ticagrelor, taken in conjunction with aspirin, reduced MACE vs aspirin alone, in patients with CAD and T2DM without prior MI or stroke.

In a retrospective cohort study, major modifiable atherosclerotic risk factors were highly prevalent among adults aged 18-44 years hospitalized for a first AMI. Except for dyslipidemia, prevalence rates of risk factors progressively increased over time.

This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.

The long-term CAROLINA trial met its primary endpoint, defined as non-inferiority of linagliptin vs. glimepiride in time to first occurrence of 3P-MACE in adults with T2DM .

Albiglutide was superior to placebo with respect to MACE in T2DM patients in the Harmony Outcomes trial without differences in serious adverse events.

Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Prof. Deanfield sheds light on the relation between T2DM and CVD, and how studies evaluating novel classes of antidiabetic drugs have evolved over time, from revealing safety signals to demonstrating CV benefit.

Prof. Neil Poulter discusses lessons that can be drawn from recent CVOTs on treatment and prevention strategies in patients with CV risk and T2DM.